B. Riley Securities resumed coverage on KORU Medical Systems with a new price target
$KRMD
Medical/Dental Instruments
Health Care
B. Riley Securities resumed coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/14/2025 | $4.50 | Overweight → Neutral | Piper Sandler |
| 7/25/2024 | $4.00 | Buy | B. Riley Securities |
| 9/7/2023 | $4.00 | Buy | Lake Street |
| 9/7/2023 | $4.50 | Buy | B. Riley Securities |
| 11/10/2022 | $3.00 → $4.00 | Hold → Buy | Canaccord Genuity |
| 11/10/2022 | $3.00 → $3.50 | Neutral → Overweight | Piper Sandler |
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
S-8 - KORU Medical Systems, Inc. (0000704440) (Filer)
10-Q - KORU Medical Systems, Inc. (0000704440) (Filer)
8-K - KORU Medical Systems, Inc. (0000704440) (Filer)
Piper Sandler downgraded KORU Medical Systems from Overweight to Neutral and set a new price target of $4.50
B. Riley Securities resumed coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00
Lake Street initiated coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00
ForCast Orthopedics, Inc. and KORU Medical Systems, Inc. (NASDAQ:KRMD) today jointly announced an agreement leveraging KORU Medical's FreedomEDGE® infusion system as part of ForCast's technology platform for the treatment of periprosthetic joint infection (PJI). PJI is a rare but serious complication of joint replacement procedures, and is challenging to treat because the infecting bacteria adhere to the prothesis and can form a protective biofilm which is resistant to standard systemic antibiotics. KORU Medical's FreedomEDGE pump will provide the infusion technology to support ForCast's proprietary delivery system for PJI treatment, known as WIIS (Wearable Intra-Articular Infusion System
BROOKLYN PARK, Minn., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cirtec Medical, a leading strategic outsourcing partner for complex minimally invasive, active implantable devices and precision components, is pleased to announce the appointment of Shar Matin as Chief Executive Officer, effective September 2, 2025. Shar brings more than 25 years of global leadership experience in the medical technology sector, with a proven track record of scaling businesses, driving innovation, and building strong customer partnerships. He most recently served as CEO of Cordis, where he led the successful transformation from a division of Cardinal Health to one of the world's largest pure-play cardiovascular compa
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2025. Financial Highlights • Second quarter 2025 net revenues of $10.2 million, a 21% increase over the prior year period • Core business (Domestic and International) net revenues of $9.3 million, a 19% increase over the prior year period • Pharma Services and Clinical Trials (PST) net revenues of $0.9 mi
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
BROOKLYN PARK, Minn., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cirtec Medical, a leading strategic outsourcing partner for complex minimally invasive, active implantable devices and precision components, is pleased to announce the appointment of Shar Matin as Chief Executive Officer, effective September 2, 2025. Shar brings more than 25 years of global leadership experience in the medical technology sector, with a proven track record of scaling businesses, driving innovation, and building strong customer partnerships. He most recently served as CEO of Cordis, where he led the successful transformation from a division of Cardinal Health to one of the world's largest pure-play cardiovascular compa
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Adam Kalbermatten as Chief Commercial Officer, effective July 28, 2025. Adam brings over two decades of commercial leadership experience in the medical device and pharmaceutical industries, with a proven track record of scaling businesses, building high-performing teams, and delivering customer-focused innovation. As Chief Commercial Officer, he will oversee all aspe
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025, according to a preliminary list of additions posted Friday, June 6, 2025. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by tot
SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)
SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)
SC 13G - KORU Medical Systems, Inc. (0000704440) (Subject)
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2025. Financial Highlights • Second quarter 2025 net revenues of $10.2 million, a 21% increase over the prior year period • Core business (Domestic and International) net revenues of $9.3 million, a 19% increase over the prior year period • Pharma Services and Clinical Trials (PST) net revenues of $0.9 mi
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report second quarter 2025 financial results on Wednesday, August 6, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for internationa
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights First quarter 2025 net revenues of $9.6 million, an 18% increase over the prior year period Core business (Domestic and International) net revenues of $9.4 million, a 21% increase over the prior year period Gross profit of $6.0 million, a 19% increase over the prior year period, and gross margin of 62.8%, a 50-basis point improvement over th